Silence Therapeutics said that the American Society for Clinical Oncology has accepted phase I data on the company's lead siRNA-based cancer drug Atu027 for presentation at its upcoming annual meeting.
The event will be held in Chicago June 3-7.
The presentation will focus on data from an ongoing phase I study with Atu027 in subjects with advanced solid cancer. “Key findings presented will include safety, tolerability and pharmacokinetic data, as well as indications of anti-tumor activity,” Silence said.
Atu027 is a blunt-ended siRNA targeting the protein kinase PKN-3
The phase I trial is an open-label study examining single and repeated intravenous infusions of Atu-027 in order to determine dose-limiting toxicities and the drug's maximum tolerated dose. Secondary outcome measures include the collection of pharmacokinetic data, safety and tolerability information, and clinical response.
Silence said late last year that 18 patients had been treated, and that the trial is expected to wrap up during the second half of 2011 (GSN 12/23/2010).